RemeGen Co., Ltd. (9995) Announces Poll Results of 2025 Third EGM

Bulletin Express12-02

RemeGen Co., Ltd. (9995) held its third extraordinary general meeting (EGM) on December 2, 2025, at the company's facility in Yantai. According to the meeting documents, a total of 563,710,243 shares were in issue, with 268,223,021 shares (approximately 47.5817% of the total) present in person or by proxy. Among these, A shares accounted for 236,190,402 and H shares accounted for 32,032,619.

The controlling shareholders and their associates, holding a combined total of 217,118,846 shares, abstained from voting on the resolution concerning expected day-to-day related party transactions for the years 2026 to 2028. Other than these abstentions, no other shareholders were required to withhold votes. The EGM considered and approved several ordinary resolutions, including the expected day-to-day related party transactions and amendments to various corporate governance policies. Each resolution received more than half of the votes cast in favor and was duly passed.

Computershare Hong Kong Investor Services Limited served as the scrutineer at the EGM, with shareholder representatives and external legal counsel participating in the count. The company’s board of directors attended the meeting, and the poll results for all resolutions were confirmed to have met the required thresholds for passage.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment